VistaGen Therapeutics Inc
Research VistaGen Therapeutics Inc (VTGN) on Bullrun: market cap USD 9.91M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVTGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.91M
- Financial periodQ1 2026
- RevenueUSD 465.00K
- Net income-USD 16.27M
- Free cash flow-USD 16.20M
Valuation Snapshot
latest market cap is USD 9.91M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 486.00K | -USD 51.42M | -USD 60.54M | n/a | -1.67 | USD 67.13M | USD 1.43M | USD 70.39M |
| FY2024 | USD 1.06M | -USD 29.36M | -USD 25.81M | n/a | -1.52 | USD 119.17M | USD 1.71M | USD 114.29M |
| FY2023 | USD 1.04M | -USD 59.25M | -USD 50.24M | n/a | -8.51 | USD 16.64M | USD 2.25M | USD 12.08M |
| FY2022 | USD 1.11M | -USD 47.76M | -USD 45.46M | n/a | n/a | USD 68.14M | USD 3.98M | USD 64.72M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 9.91M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 26.15M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 83.53M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 138.90M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 20.68M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 402.69M | n/a | n/a | n/a |
About VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VistaGen Therapeutics Inc's market cap?
VistaGen Therapeutics Inc's market capitalization is USD 9.91M.
What does VistaGen Therapeutics Inc do?
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.